MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Survival

Poor Prognostic Factors in Patients with Malignant Pleural Mesothelioma Classified as Pathological Stage IB According to the Eighth Edition TNM Classification

Annals of Surgical Oncology 2018 April 3 [Epub ahead of print] [Link] Takuwa T, Hashimoto M, Kuroda A, Nakamura A, Nakamichi T, Fukuda A, Matsumoto S, Kondo N, Hasegawa S Abstract INTRODUCTION: The change in TNM classification of malignant pleural mesothelioma (MPM) between the seventh and eighth edition classifications has resulted in the downstaging of […]

Comments Off on Poor Prognostic Factors in Patients with Malignant Pleural Mesothelioma Classified as Pathological Stage IB According to the Eighth Edition TNM Classification

Immunohistochemical Expression of Aquaporin-1 in Fluoro-Edenite-Induced Malignant Mesothelioma: A Preliminary Report

International Journal of Molecular Sciences 2018 February [Link] Angelico G, Caltabiano R, Loreto C, Ieni A, Tuccari G, Ledda C, Rapisarda V Abstract BACKGROUND: The immunohistochemical expression of aquaporin-1 (AQP1) in asbestos-related malignant pleural mesothelioma (MPM) is emerging as a useful prognostic indicator of improved survival. A significantly increased incidence of MPM in a small […]

Comments Off on Immunohistochemical Expression of Aquaporin-1 in Fluoro-Edenite-Induced Malignant Mesothelioma: A Preliminary Report

The C-Reactive Protein/Albumin Ratio is a Novel Significant Prognostic Factor in Patients with Malignant Pleural Mesothelioma: A Retrospective Multi-institutional Study

Annals of Surgical Oncology 2018 March [Epub ahead of print] [Link] Takamori S et. al. Abstract BACKGROUND: Malignant pleural mesothelioma (MPM), a devastating neoplasm, is traditionally considered to be resistant to antitumor therapy. Identification of clinical prognostic indicators is therefore needed. Although the C-reactive protein/albumin ratio (CAR) has been used to predict the prognosis of […]

Comments Off on The C-Reactive Protein/Albumin Ratio is a Novel Significant Prognostic Factor in Patients with Malignant Pleural Mesothelioma: A Retrospective Multi-institutional Study

Prognostic Impact of Inflammation-related Biomarkers on Overall Survival of Patients with Inoperable Malignant Pleural Mesothelioma

In Vivo 2018 March [Link] Otoshi T, Kataoka Y, Kaku S, Iki R, Hirabayashi M Abstract AIM: The aim of the present study was to assess the prognostic utility of the pretreatment blood neutrophil-to-lymphocyte ratio (NLR) and the C-reactive protein-to-albumin ratio (CAR) in patients with inoperable malignant pleural mesothelioma (MPM). MATERIALS AND METHODS: The medical […]

Comments Off on Prognostic Impact of Inflammation-related Biomarkers on Overall Survival of Patients with Inoperable Malignant Pleural Mesothelioma

Survival prediction in mesothelioma using a scalable Lasso regression model: instructions for use and initial performance using clinical predictors

BMJ Open Respiratory Research 2018 January [Link] Kidd AC, McGettrick M, Tsim S, Halligan DL, Bylesjo M, Blyth KG Abstract INTRODUCTION: Accurate prognostication is difficult in malignant pleural mesothelioma (MPM). We developed a set of robust computational models to quantify the prognostic value of routinely available clinical data, which form the basis of published MPM […]

Comments Off on Survival prediction in mesothelioma using a scalable Lasso regression model: instructions for use and initial performance using clinical predictors

Global Trends in Mortality from Malignant Mesothelioma; Analysis of WHO Mortality Database (1993-2013)

The Clinical Respiratory Journal 2018 February 9 [Epub ahead of print] [Link] Abdel-Rahman O Abstract BACKGROUND: Malignant mesothelioma is an aggressive malignancy that is predisposed to through asbestos exposure. Little is known about the extent to which asbestos use ban has affected global trends in malignant mesothelioma. The current study investigated recent global mortality trends […]

Comments Off on Global Trends in Mortality from Malignant Mesothelioma; Analysis of WHO Mortality Database (1993-2013)

Management and Survival of Pleural Mesothelioma: A Record Linkage Study

Respiration, International Review of Thoracic Diseases 2018 February 8 [Epub ahead of print] [Link] Carioli G, Bonifazi M, Rossi M, Zambelli A, Franchi M, Zocchetti C, Gasparini S, Corrao G, La Vecchia C, Negri E Abstract BACKGROUND: Pleural mesothelioma (PM) is a rare, highly lethal tumor. A definite consensus on its management has yet to […]

Comments Off on Management and Survival of Pleural Mesothelioma: A Record Linkage Study

Evaluating quality of life and cost implications of prophylactic radiotherapy in mesothelioma: Health economic analysis of the SMART trial

PLoS One 2018 February 5 [Link] Stewart SA, Clive AO, Maskell NA, Penz E Abstract BACKGROUND: The SMART trial is a UK-based, multicentre RCT comparing prophylactic radiotherapy and symptom-based (deferred) radiotherapy in 203 patients with Malignant Pleural Mesothelioma who had undergone large bore pleural interventions. Using costs and quality of life data collected alongside the […]

Comments Off on Evaluating quality of life and cost implications of prophylactic radiotherapy in mesothelioma: Health economic analysis of the SMART trial

Progress in the Management of Advanced Thoracic Malignancies in 2017

Journal of Thoracic Oncology 2018 January 10 [Epub ahead of print] [Link] Ferrara R, Mezquita L, Besse B Abstract The treatment paradigm of non-small cell lung cancer (NSCLC) underwent a major revolution during the course of 2017. Immune checkpoint inhibitors (ICIs) brought remarkable improvements in response and overall survival (OS) both in unselected pretreated patients […]

Comments Off on Progress in the Management of Advanced Thoracic Malignancies in 2017

Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma

Journal of Thoracic Oncology 2017 December [Epub ahead of print] [Link] Tsao AS et.al. Abstract Window-of-opportunity trials in malignant pleural mesothelioma (MPM) are challenging but can yield important translational information about a novel agent. We treated MPM patients (n=24) with 4 weeks of oral dasatinib followed by surgery with or without radiotherapy and then an […]

Comments Off on Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma